PARIS--(BUSINESS WIRE)--Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will participate in the RBC Capital Markets 2016 Healthcare Conference in New York on February 23rd and 24th, and in the Credit Suisse Healthcare Conference in London on March 1st and 2nd.
At the RBC Capital Markets 2016 Healthcare conference, Prof. Ehrlich is scheduled to participate in a fireside chat with RBCCM healthcare analyst Douglas Miehm at 8:30 AM (EST) on February 23rd. This conversation will be webcast, and will be available on ABIVAX’s website. Additionally, Prof. Ehrlich and ABIVAX’s CFO, Alain Chevallier, will conduct one-on-one meetings with interested investors over the course of the conference.
At the Credit Suisse Healthcare conference in London, Prof. Ehrlich and Mr. Chevallier will meet with investors in one-on-one meetings over the course of the conference.
is an emerging global leader in the discovery, development and
commercialization of anti-viral therapeutics and vaccines to treat some
of the world’s most life-threatening infectious diseases, including
HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical
stage research: ABX464 a novel first-in-class resistance-proof oral
small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that
could cure chronic Hepatitis B. ABIVAX also is advancing additional
anti-viral compounds and therapeutic vaccines that may enter the
clinical stage in the coming 18 months.
Follow us on Twitter @ABIVAX_